CY1121411T1 - Σταθερες φαρμακοτεχνικες μορφες πολυπεπτιδιων και χρησεις αυτων - Google Patents

Σταθερες φαρμακοτεχνικες μορφες πολυπεπτιδιων και χρησεις αυτων

Info

Publication number
CY1121411T1
CY1121411T1 CY20191100137T CY191100137T CY1121411T1 CY 1121411 T1 CY1121411 T1 CY 1121411T1 CY 20191100137 T CY20191100137 T CY 20191100137T CY 191100137 T CY191100137 T CY 191100137T CY 1121411 T1 CY1121411 T1 CY 1121411T1
Authority
CY
Cyprus
Prior art keywords
formulations
formulation
tween
polypeptides
pharmaceutical
Prior art date
Application number
CY20191100137T
Other languages
English (en)
Inventor
Ann BRIGÉ
Christine Labeur
Veronique De Brabandere
Original Assignee
Ablynx N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx N.V. filed Critical Ablynx N.V.
Publication of CY1121411T1 publication Critical patent/CY1121411T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

Παρέχονται φαρμακοτεχνικές μορφές οι οποίες περιέχουν μονές μεταβλητές περιοχές με καλή διαλυτότητα και καλή σταθερότητα κάτω από διαφορετικές συνθήκες αποθήκευσης, μεταφοράς και συνθήκες τάσης. Οι φαρμακοτεχνικές μορφές είναι χρήσιμες ως φαρμακευτική φαρμακοτεχνική μορφή. Η φαρμακοτεχνική μορφή αποτελείται από έναν υδατικό φορέα με pΗ 5.5 έως 8.0, ένα ρυθμιστικό που επιλέγεται από την ομάδα που αποτελείται από ιστιδίνη με pΗ 6.0-6.5, hepes με pΗ 7.0-8.0, MES με pΗ 6.0, ηλεκτρικό με pΗ 6.0-6.5 και οξικό με pΗ 5,5-6.0, ένα έκδοχο, και/ή ένα επιφανειοδραστικό που επιλέγεται από Tween 80, Tween 20 και πολοξαμερή. Η φαρμακοτεχνική μορφή χαρακτηρίζεται περαιτέρω από το ότι έχει συγκέντρωση ανόργανου άλατος 150 mM ή χαμηλότερη. Η εφεύρεση περαιτέρω αφορά περιέκτες και φαρμακευτικές μονάδες που αποτελούνται από τέτοιες φαρμακοτεχνικές μορφές και μεθόδους για την παρασκευή και προφυλακτικές και θεραπευτικές χρήσεις των φαρμακοτεχνικών μορφών και φαρμακευτικών μονάδων της εφεύρεσης.
CY20191100137T 2009-09-03 2019-01-31 Σταθερες φαρμακοτεχνικες μορφες πολυπεπτιδιων και χρησεις αυτων CY1121411T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27581609P 2009-09-03 2009-09-03
US28450209P 2009-12-18 2009-12-18
PCT/EP2010/062975 WO2011026948A1 (en) 2009-09-03 2010-09-03 Stable formulations of polypeptides and uses thereof
EP10747896.8A EP2473528B1 (en) 2009-09-03 2010-09-03 Stable formulations of polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CY1121411T1 true CY1121411T1 (el) 2020-05-29

Family

ID=42797362

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100137T CY1121411T1 (el) 2009-09-03 2019-01-31 Σταθερες φαρμακοτεχνικες μορφες πολυπεπτιδιων και χρησεις αυτων

Country Status (12)

Country Link
US (2) US9884117B2 (el)
EP (5) EP3725330A1 (el)
CY (1) CY1121411T1 (el)
DK (2) DK2473528T3 (el)
ES (3) ES2531083T3 (el)
HK (1) HK1204284A1 (el)
HR (1) HRP20190137T1 (el)
LT (1) LT2805731T (el)
PL (2) PL3438126T3 (el)
PT (3) PT3438126T (el)
SI (1) SI2805731T1 (el)
WO (2) WO2011026945A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8629244B2 (en) * 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
CN102271707B (zh) 2008-10-29 2015-04-08 阿布林克斯公司 单域抗原结合性分子的制剂
JP6113404B2 (ja) 2008-10-29 2017-04-12 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の精製方法
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
SG174862A1 (en) 2009-04-10 2011-11-28 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
ES2531083T3 (es) * 2009-09-03 2015-03-10 Ablynx Nv Formulaciones estables de polipéptidos y usos de las mismas
US20110059079A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
EP3501499B1 (en) 2010-02-11 2022-09-07 Ablynx NV Methods and compositions for the preparation of aerosols
SI2542257T1 (en) 2010-03-01 2018-01-31 Bayer Healthcare Llc Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
EA201390810A1 (ru) * 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
DK2646052T3 (en) 2010-12-02 2017-07-17 Oncolytics Biotech Inc LYOPHILIZED VIRAL FORMULATIONS
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
KR20140054026A (ko) * 2011-07-07 2014-05-08 알에보 바이올로직스, 인코포레이티드 단백질을 안정화시키는 제제
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP3003369A4 (en) * 2013-05-28 2017-04-26 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions comprising pyrophosphate
EP3209327A1 (en) 2014-10-21 2017-08-30 Ablynx N.V. Treatment of il-6r related diseases
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP3589725A1 (en) * 2017-02-28 2020-01-08 Vib Vzw Means and methods for oral protein delivery
MX2019014400A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Inmunoglobulinas que se unen a adamts.
BR112021016198A2 (pt) * 2019-03-08 2021-11-03 Boehringer Ingelheim Int Gmbh Formulações de anticorpo anti-il-36r
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001985A1 (fr) 1980-01-04 1981-07-23 Marchal Equip Auto Dispositif d'arret en fin de course pour motoreducteur destine notamment a un essuie-glace
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DK0937140T3 (da) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE461282T1 (de) 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
EP1169453A1 (en) 1999-04-22 2002-01-09 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
DE60138333D1 (de) 2000-03-14 2009-05-28 Unilever Nv Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1360207B1 (en) 2000-12-13 2011-06-22 Bac Ip B.V. Protein arrays of camelid heavy-chain immunoglobulin variable domains
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
WO2003025020A1 (fr) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
ES2392073T3 (es) * 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
NZ563471A (en) * 2002-11-08 2009-04-30 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
AU2004204262B2 (en) 2003-01-10 2010-11-04 Ablynx N.V. Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
ES2349779T5 (es) 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
DK1687338T3 (da) 2003-11-07 2011-02-07 Ablynx Nv Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP4829897B2 (ja) 2005-01-14 2011-12-07 アブリンクス ナームローゼ フェンノートシャップ 血小板減少及び／又はフォンビルブラント因子（ｖＷＦ）と血小板との間の自発的相互作用によって特徴づけられる疾患及び障害の異なる形態を区別する方法及びアッセイ
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
MX348154B (es) * 2005-06-21 2017-05-30 Xoma (Us) Llc Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
AU2006301426A1 (en) * 2005-10-11 2007-04-19 Ablynx N.V. NanobodiesTM and polypeptides against EGFR and IGF-IR
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
SE530085C2 (sv) 2006-01-30 2008-02-26 Timothy Richard Vinnicombe Kärl för microvågsugn
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CA2644405A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
KR100817251B1 (ko) 2006-06-28 2008-03-27 주식회사 삼정산업 철재 파렛트
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
WO2008028977A2 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
JP2010504361A (ja) 2006-09-25 2010-02-12 メディミューン，エルエルシー 安定した抗体製剤およびその使用
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
WO2008070721A2 (en) 2006-12-06 2008-06-12 Wyeth High protein concentration formulations containing mannitol
WO2008071685A1 (en) 2006-12-13 2008-06-19 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
WO2008074868A1 (en) * 2006-12-20 2008-06-26 Ablynx N.V. Oral delivery of polypeptides
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
JP5645409B2 (ja) * 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
US8906680B2 (en) 2006-12-22 2014-12-09 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CN101796072B (zh) * 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
US20110282033A1 (en) 2007-05-24 2011-11-17 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
NZ601913A (en) 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
EP2238156B1 (en) * 2008-01-29 2014-10-01 Ablynx N.V. Methods to stabilize proteins and polypeptides
WO2009099641A2 (en) 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
CA2717015A1 (en) * 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
CN101977654A (zh) 2008-03-21 2011-02-16 埃博灵克斯股份有限公司 冯威勒布兰特因子特异性结合物及其应用方法
CN102271707B (zh) 2008-10-29 2015-04-08 阿布林克斯公司 单域抗原结合性分子的制剂
BRPI0921319A2 (pt) * 2008-11-26 2018-10-16 Glaxo Group Ltd composição, método para dispensação de uma composição, e para tratar, prevenir ou diagnosticar uma condição ocular, e, processo para produzir uma composição farmacêutica
PT2387583T (pt) * 2009-01-14 2018-12-24 Ablynx Nv Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos
WO2010088444A1 (en) * 2009-01-29 2010-08-05 Medimmune, Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
EP2403873A1 (en) * 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
ES2531083T3 (es) * 2009-09-03 2015-03-10 Ablynx Nv Formulaciones estables de polipéptidos y usos de las mismas

Also Published As

Publication number Publication date
US20120201812A1 (en) 2012-08-09
EP2473527A1 (en) 2012-07-11
EP2805731A2 (en) 2014-11-26
EP2805731A3 (en) 2015-04-01
PL2473528T3 (pl) 2015-05-29
EP2473528A1 (en) 2012-07-11
SI2805731T1 (sl) 2019-02-28
HK1204284A1 (en) 2015-11-13
EP2805731B1 (en) 2018-10-31
WO2011026948A1 (en) 2011-03-10
EP3725330A1 (en) 2020-10-21
WO2011026945A1 (en) 2011-03-10
ES2531083T3 (es) 2015-03-10
EP2473527B1 (en) 2016-11-30
US9884117B2 (en) 2018-02-06
HRP20190137T1 (hr) 2019-03-22
LT2805731T (lt) 2019-02-11
EP2473528B1 (en) 2014-12-03
EP3438126A1 (en) 2019-02-06
EP3438126B1 (en) 2020-08-19
PL3438126T3 (pl) 2021-03-08
DK2473527T3 (en) 2017-03-06
DK2473528T3 (en) 2015-03-02
ES2617180T3 (es) 2017-06-15
ES2831323T3 (es) 2021-06-08
PT3438126T (pt) 2020-11-09
PT2473528E (pt) 2015-03-04
PT2473527T (pt) 2017-02-27
US20120244158A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
CY1121411T1 (el) Σταθερες φαρμακοτεχνικες μορφες πολυπεπτιδιων και χρησεις αυτων
CY1123774T1 (el) Στελεχη shigella me υπερφυσαλιδωση
CY1124011T1 (el) Συνθεσεις γλυκοπεπτιδιου
CY1124206T1 (el) Αναστολεις πυριδοπυριμδινονης cdk2/4/6
CY1123407T1 (el) Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης
CY1124844T1 (el) Φαρμακευτικο σκευασμα αντισωματος
CY1121420T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
CY1121230T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου
CY1121782T1 (el) Διαδικασια για ξηρανση της bibw2992, tων αλατων αυτης και στερεων φαρμακευτικων σκευασματων που περιλαμβανουν αυτο το δραστικο συστατικο
CY1117934T1 (el) Αντιβακτηριακες φαρμακευτικες συνθεσεις
BR112016008849B8 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
WO2016107818A8 (en) Compositions and methods for protein glycosylation
MX2020002924A (es) Lactamas fusionadas de arilo y heteroarilo.
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
CY1114244T1 (el) Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση
DK1954308T3 (da) Stabiliseringsmidler til frysetørrede vacciner
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
CO6660498A2 (es) Estabilización de inmunoglobulinas a través de una formulación acuosa con histidina a un ph entre débilmente ácido y neutro
MX354867B (es) Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
NI201300034A (es) Conjugado de naloxol - peg cristalino
CY1120132T1 (el) Χρηση ρ3 πρωτεϊνων συντηξης βακτηριοφαγου ως παραγοντων δεσμευσης αμυλοειδους
BR112014014319A2 (pt) composições de cuidado oral
WO2013192517A3 (en) Compounds for treating infectious diseases
CO2023005373A2 (es) Proteínas f de hmpv estabilizadas por prefusión